Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AGEN2373 · 1 trial · 1 indication
DLT in patient in dose escalation phase
According to NCI-CTCAE Version 5.0, vital signs (blood pressure, heartrate, and temperature), physical examinations, 12-lead electrocardiogram, Eastern Cooperative Oncology Group (ECOG) performance status, and clinical laboratory assessments for all dose groups
According to NCI-CTCAE Version 5.0, vital signs (blood pressure, heartrate, and temperature), physical examinations, 12-lead electrocardiogram, Eastern Cooperative Oncology Group (ECOG) performance status, and clinical laboratory assessments for all dose groups
According to NCI-CTCAE Version 5.0, vital signs (blood pressure, heartrate, and temperature), physical examinations, 12-lead electrocardiogram, Eastern Cooperative Oncology Group (ECOG) performance status, and clinical laboratory assessments for all dose groups
| Arm | Type | Description |
|---|---|---|
| 2-Week Monotherapy with AGEN2373 | EXPERIMENTAL | 3+3 Dose escalation of AGEN2373 administered by IV. |
| 3-Week Monotherapy with AGEN2373 | EXPERIMENTAL | 3+3 Dose escalation of AGEN2373 administered by IV. |
| 4-Week Monotherapy with AGEN2373 | EXPERIMENTAL | 3+3 Dose escalation of AGEN2373 administered by IV. |
| Combination Therapy with 3-week AGEN2373 Monotherapy Lead-In Combination with 6-week Botensilimab | EXPERIMENTAL | 3+3+3 Dose escalation of AGEN2373. AGEN2373 and botensilimab administered by IV. |
| Combination Therapy with 3-week AGEN2373 in combination with 6-week Botensilimab | EXPERIMENTAL | 3+3+3 Dose escalation of AGEN2373. AGEN2373 and botensilimab administered by IV. |
| Name | Type | Description |
|---|---|---|
| AGEN2373 | DRUG | An Anti-CD137 Monoclonal Antibody |
| Botensilimab | DRUG | Anti-CTLA-4 Monoclonal Antibody |
Inclusion Criteria: 1. Voluntarily agree to participate by giving signed, dated, and written informed consent prior to any study specific procedures. Participation in pharmacogenomics testing is optional. 2. ≥ 18 years of age. 3. Histologically or cytologically confirmed diagnosis of a solid tumor ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
AGEN2373 is an investigational small molecule being developed for the treatment of advanced cancer. It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities and is still being studied for safety and efficacy in patients.
AGEN2373 is a small molecule that targets CD137 and CTLA-4, as indicated by the clinical trial title. These are immune checkpoint targets involved in regulating T-cell responses, and modulating them is intended to enhance the immune system's ability to fight cancer cells.
AGEN2373 is being developed by Agenus Inc., a biopharmaceutical company. The company's stock is traded under the ticker symbol AGEN. Agenus is conducting clinical research to evaluate the drug's potential in treating advanced cancer.
AGEN2373 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory bodies. The Phase 1 trial is designed to assess the drug's safety, tolerability, and preliminary efficacy in patients with advanced cancer.
AGEN2373 has been studied in one completed Phase 1 clinical trial with the identifier NCT04121676. The trial, titled 'Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer,' enrolled 91 participants in the United States. The study was controlled but not randomized or double-blinded.
AGEN2373 is being studied in a trial that combines anti-CD137 and anti-CTLA-4 monoclonal antibodies, but AGEN2373 itself is described as a small molecule. The trial evaluates the combination of these antibodies in patients with advanced cancer, and AGEN2373 is part of this investigational approach.